Clinical Trial Update: 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for alpelisib (Piqray) targeting TIE2/PIK3CA pathway–driven vascular anomalies. The study is sponsored by Children's Hos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vascular Anomalies
• Vascular Anomaly

Drugs mentioned

• Alpelisib (Piqray) (alpelisib)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Vascular Anomalies, Vascular Anomaly | Phase 2 | Status: ACTIVE_NOT_RECRUITING